IP Library Granted Patent US 9,579,343
Granted Patent B2
US 9,579,343 · App. 14/481,071 · Granted Feb 28, 2017

Direct compression polymer tablet core

Inventors: Joseph Tyler (Somerville, MA); John S. Petersen (Acton, MA)
Assignee: GENZYME CORPORATION
A61K31/785A61K9/2009A61K9/2013A61K9/2027A61K9/28A61K9/282A61K9/2866
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,579,343
App. No.
14/481,071
Granted
Feb 28, 2017
Kind
B2
Abstract

The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.

Claims (24)

1. A tablet, comprising:

i) a hydrophilic, compressed core consisting essentially of:

a) at least 95 wt. % sevelamer hydrochloride; and

b) one or more excipients, comprising stearic acid or colloidal silicon dioxide; and

ii) a water-based coating, comprising hydroxypropylmethylcellulose or diacetylated monoglyceride.

2. The tablet of claim 1 , wherein the sevelamer hydrochloride is hydrated.

3. The tablet of claim 1 , wherein the sevelamer hydrochloride comprises a moisture content of about 5 wt. % or greater.

4. The tablet of claim 1 , wherein the sevelamer hydrochloride has a moisture content of about 5 wt. % to about 9 wt. %.

5. The tablet of claim 1 , wherein the water-based coating comprises hydroxypropylmethylcellulose and diacetylated monoglyceride.

6. The tablet of claim 1 , wherein the hydrophilic, compressed core has a hardness of at least 150 N.

7. The tablet of claim 1 , wherein the hydrophilic, compressed core has a hardness of 150-170 N.

8. The tablet of claim 1 , wherein the hydrophilic, compressed core has a friability of no more than 0.8%.

9. The tablet of claim 1 , wherein the largest dimension of the hydrophilic, compressed core is at least 0.3125 inches.

10. The tablet of claim 1 , wherein the largest dimension of the hydrophilic, compressed core is at least 0.620 inches.

11. The tablet of claim 1 , wherein the hydrophilic, compressed core is formed from a 0.3125 in×0.750 in punch.

12. The tablet of claim 1 , wherein the tablet is useful in removing phosphate from a patient in need thereof.

13. The tablet of claim 1 , wherein the hydrophilic, compressed core comprises 400 mg or 800 mg of the sevelamer hydrochloride on an anhydrous basis.

14. The tablet of claim 1 , wherein the hydrophilic, compressed core comprises 400 mg of the sevelamer hydrochloride on an anhydrous basis.

15. The tablet of claim 1 , wherein the hydrophilic, compressed core comprises 800 mg of the sevelamer hydrochloride on an anhydrous basis.

16. The tablet of claim 15 , wherein the largest dimension of the hydrophilic, compressed core is 0.750 inches.

17. The tablet of claim 15 , wherein the water-based coating comprises hydroxypropylmethylcellulose and diacetylated monoglyceride.

18. The tablet of claim 14 , wherein the largest dimension of the hydrophilic, compressed core is 0.750 inches.

19. The tablet of claim 18 , wherein the water-based coating comprises hydroxypropylmethylcellulose and diacetylated monoglyceride.

20. The tablet of claim 1 , wherein the largest dimension of the hydrophilic, compressed core is 0.750 inches.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2015
From: TYLER, JOSEPH; PETERSEN, JOHN S.
To: GELTEX PHARMACEUTICALS, INC.
Reel/Frame 037250/0451 →
MERGER Recorded Dec 9, 2015
From: GELTEX PHARMACEUTICALS, INC.
To: GENZYME CORPORATION
Reel/Frame 037250/0641 →
Continuity (8)
Continuation 13467448 · May 9, 2012
Continuation 12461143 · Aug 3, 2009
Continuation 11196799 · Aug 3, 2005
Continuation 10785322 · Feb 24, 2004
Continuation 09691429 · Oct 18, 2000
Provisional Application 60174227 · Jan 3, 2000
Provisional Application 60160258 · Oct 19, 1999
Related Publication 20150056278A1 · Feb 26, 2015